Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma

NCT04552223 is registered in ClinicalTrials.gov with Jose Lutzky, MD as lead sponsor.

NCT NCT04552223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04552223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma
Lead sponsor
Jose Lutzky, MD
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2020
Completion date
January 4, 2026
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma